$Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features$

Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2012-06, Vol.26 (6), p.1442-1444
Hauptverfasser:	Woyach, J A, Lozanski, G, Ruppert, A S, Lozanski, A, Blum, K A, Jones, J A, Flynn, J M, Johnson, A J, Grever, M R, Heerema, N A, Byrd, J C
Format:	Artikel
Sprache:	eng
Schlagworte:	631/208/1405 692/699/67/1059/99 692/699/67/1990/283/1895 692/700/1750 Analysis Antimitotic agents Antineoplastic agents Antineoplastic Agents - therapeutic use Ataxia Telangiectasia Mutated Proteins Biomarkers, Tumor - genetics Cancer Cancer Research Care and treatment Cell Cycle Proteins - genetics Chromosome Deletion Chronic lymphocytic leukemia Critical Care Medicine Cyclin-dependent kinases Cytogenetic Analysis Cytogenetics Development and progression DNA-Binding Proteins - genetics Dosage and administration Drug Resistance, Neoplasm - genetics Drug therapy Flavonoids - therapeutic use Flavopiridol Genetic aspects Hematology Humans Immunological adjuvants In Situ Hybridization, Fluorescence Intensive Internal Medicine Kinases letter-to-the-editor Letters to the editor Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - genetics Leukemia, Lymphocytic, Chronic, B-Cell - mortality Lymphatic leukemia Medical prognosis Medicine Medicine & Public Health Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Oncology Patient outcomes Piperidines - therapeutic use Protein Serine-Threonine Kinases - genetics Response rates Risk Factors Survival Rate Treatment Outcome Tumor Suppressor Protein p53 - genetics Tumor Suppressor Proteins - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!